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Objectives: To determine whether high-sensitivity C-reactive protein (hs-CRP) concentrations 
differ between Chinese, Malays, and Indians with and without type 2 diabetes mellitus and to 
look for an association with demographic, metabolic and therapeutic variables.
Methods: Phase 1: We retrieved records of 50 Chinese, 51 Malay, and 67 Indian individuals 
who had routine health screening blood tests. Phase 2: We recruited 111 Chinese, 68 Malays, 
and 67 Indians with type 2 diabetes mellitus and measured their hs-CRP in addition to standard 
laboratory tests.
Results: Phase 1: The median hs-CRP was 0.6 mg/L (0.2–6.2) in Chinese, 1.2 mg/L (0.2–7.9) 
in Malays, and 1.9 mg/L (0.2–10.0) in Indians. The Indians had higher hs-CRP compared to 
Chinese (P , 0.05) when adjusted for age, sex, body mass index (BMI), lipids, blood pressure, 
and smoking, and a significant correlation was seen between female sex, smoking status, fast-
ing glucose and triglyceride concentration, and hs-CRP in all three ethnicities. Phase 2: The 
median hs-CRP was 1.2 mg/L (0.2–9.9) in Chinese, 2.2 mg/L (0.2–9.0) in Malays, and 2.3 mg/L 
(0.2–9.8) in Indians. Indians had higher hs-CRP when compared to Chinese (P , 0.05) and a 
significant   correlation was seen between BMI, female gender, diabetes, and the use of metformin 
and hs-CRP in all three ethnicities (P , 0.05) when adjusted for the above variables and use of 
aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (ACE-I/ARB), 
statin, metformin, rosiglitazone, sulfonylurea, glinides, acarbose, and insulin.
Conclusion: hs-CRP concentrations are significantly higher in Indians compared to the Chinese 
(in both the diabetic and nondiabetic individuals) after adjustment for the various demographic, 
metabolic, and therapeutic variables.
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Introduction
Singapore is a small and densely populated country of 4.59 million people. There are 
three major ethnic groups: 75% Chinese, 13.7% Malays, 8.7% Indians (South Asians 
who trace their ancestry from the Indian subcontinent), and 2.6% others (http://www.
singstat.gov.sg).
In Singapore, it has been seen that Indians are at increased risk of developing 
coronary heart disease (CHD) when compared to other populations.1 On average, 
Indians are at three-fold risk and Malays two-fold risk when compared to Chinese. 
  Previous cross-sectional studies have shown that the greater susceptibility of 
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(cigarette smoking, hypertension or hypercholesterolemia)2 
or by hyperhomocysteinemia.3
Indians have been shown to have a high risk of developing 
CHD with or without diabetes.4–6 High-sensitivity C-reactive 
protein (hs-CRP) is one of the strongest univariate predictors 
of risk of cardiovascular events in both men and women,5–8 
and higher hs-CRP concentrations have been reported for 
Asian Indians when compared to other populations in vari-
ous studies.5,9–11 However, there is presently still no published 
data of a comparison of hs-CRP concentrations in the three 
major ethnic groups of Singapore.
In this study, we sought to determine if hs-CRP was dif-
ferent in the three racial groups, regardless of whether they 
had diabetes.
Patients and methods
Phase 1: We selected 168 consecutive individuals (50   Chinese, 
51 Malays, and 67 Indians) from our health screening center 
who had a serum hs-CRP measured. We looked retrospec-
tively into their records for their demographic data (age, 
sex), smoking history, body mass index (BMI), blood 
pressure, hs-CRP concentration, fasting lipids and glucose 
concentrations.
The patients had their blood drawn after a 10-hour over-
night fast. Serum glucose concentration was measured by 
glucose oxidase using the oxygen rate method. Serum lipids 
were measured using the standard coupled enzymatic methods. 
Low-density lipoprotein cholesterol (LDL-C) was calculated 
by using the Friedewald equation. Therefore, when the fasting 
triglyceride concentration was above 4.5 mmol/L, the LDL-C 
was not estimated. We excluded patients with a fasting glucose 
of .7.0 mmol/L or a history of type 2 diabetes mellitus.   Smoking 
history and ethnicity was self reported by the individuals.
Phase 2: We recruited 246 consecutive individuals with type 
2 diabetes mellitus (111 Chinese, 68 Malays, and 67 Indians) 
from our Diabetes and Endocrine Centre and included an hs-
CRP test to their routine blood draw. We reviewed their records 
for demographic data (age, sex), smoking history, BMI, gly-
cated hemoglobin (HbA1c), lipid profile, blood pressure, and 
medication history such as antidiabetic agents (metformin, 
sulfonylurea, rosiglitazone, acarbose, glinide or insulin), 
angiotensin-converting enzyme inhibitor (ACE-I), angiotensin 
receptor blocker (ARB), aspirin, and statin. All the participants 
signed an informed written consent. The study was ethically 
approved by our institutional review board.
The patient’s smoking history was based on self 
reports. Ethnicity classification was based on their 
National   Identification Cards. HbA1c was checked by 
immunoturbidometric measurement on the Beckman Coulter 
Synchron LX®20 (Beckman Coulter, Inc., Brea, CA, USA) 
clinical chemistry analyzer in our laboratory. Serum lipids 
were measured after a 10-hour overnight fast and was also 
measured using standard coupled enzymatic methods. LDL-C 
was calculated by the Friedewald equation. hs-CRP was 
measured by near infrared particle immunoassay. All values 
of hs-CRP which were higher than 10 mg/L were excluded 
from the study because such an elevation of hs-CRP might 
also result from a possible systemic infection. As we do not 
have information regarding the income and standard of living 
for every individual, we used government subsidies as a sur-
rogate marker. A patient who received government subsidies 
for their health care (subsidized patients) was deemed to have 
a lower socioeconomic status than a patient who received no 
subsidy (private patients).
The distribution of hs-CRP in this study was very highly 
skewed to the left (see Figure 1). Robust regression analysis 
was applied to analyze the data. Unlike the conventional 
multiple regression model based on ordinary least squares 
(OLS), the proposed robust model is designed to accom-
modate outlying observations which are often observed with 
skewed variables.12,13 Estimated with iterative reweighted least 
squares (IRWLS) algorithm, the proposed robust model was 
able to generate more reliable estimates about the influence of 
ethnicity on hs-CRP, after adjusting for all relevant variables 
in Phase 1, Phase 2 and in both groups combined together. 
The proposed robust model has several advantages over the 
conventional approach in data analysis. Firstly, it analyzes 
the skewed outcome directly without the need to perform 
back-transformation for interpretation. This is desirable 
because arithmetic transformation may not necessarily induce 
  normality in the skewed outcome. Secondly, it does not discard 
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Figure 1 histogram showing that the high-sensitivity c-reactive protein (hs-crP) 
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any observations in the   process even if they are confirmed 
outliers. Lastly, it does not impose any strict distributional 
assumption on the outcome like generalized linear model 
(GLM), as there is no precise information about the outcome’s 
probabilistic characteristics. This in turn offers much flexibil-
ity and convenience in data analysis.12,13 Analyzed with Stata 
10.0 (Stata Corp, College Station, TX, USA), all statistical 
tests were conducted at 5% level of significance.
Results
The baseline characteristics of patients with or without 
diabetes of each ethnic group are provided in Table 1 and 
Table 2. In Phase 1, the median hs-CRP was 0.6 mg/L 
(0.2–6.2) in Chinese, 1.2 mg/L (0.2–9.9) in Malays, and 
1.9 mg/L   (0.2–10.0) in Indians (Figure 2A). In Phase 2, the 
median hs-CRP was 1.2 mg/L (0.2–9.9) in Chinese, 2.2 mg/L 
(0.2–7.9) in Malays, and 2.3 mg/L (0.2–9.8) in Indians 
(Figure 2B). The number of current smokers was higher in 
Phase 1 when compared to Phase 2, likely due to counseling 
measures to stop smoking in patients with diabetes mellitus. 
There were generally more subsidized patients when com-
pared to private patients in all ethnicities.
In the Indian subgroup, there were more private patients 
(38.8%) when compared to the Chinese (28.8%) and 
Malays (10.3%). The mean BMI was higher in the Malays 
(30.4 kg/m2) when compared to the Indians (26.7 kg/m2) and 
the Chinese in patients with diabetes mellitus (26.3 kg/m2). 
The mean systolic and diastolic blood pressure was com-
parable in all three ethnicities but was higher in those with 
diabetes. The mean HbA1c was highest in the Malays (8.5%) 
when compared to the Indians (8.0%) and Chinese (7.9%). 
The mean fasting glucose in patients without diabetes was 
highest in the Indians (5.5 mmol/L) when compared to the 
Chinese (4.9 mmol/L) and Malays (5.2 mmol/L). The mean 
total triglyceride was higher and the mean high-density lipo-
protein (HDL) cholesterol was lower in patients with diabetes. 
The lower concentrations of LDL-C and total cholesterol in 
patients with diabetes may be treatment-related as 82.5% of 
them were on statins. The use of various drugs in patients in 
various ethnic groups was comparable.
We saw a significant positive association of hs-CRP 
in patients with diabetes mellitus (P = 0.03), female 
sex (P = 0.001), Indian ethnicity (P , 0.001), and BMI 
(P , 0.001) after adjusting for smoking status, age, sex, 
Table 1 Baseline characteristics
All 
Phase 1 
All 
Phase 2
Chinese 
Phase 1
Chinese 
Phase 2
Malay 
Phase 1
Malay 
Phase 2
Indian 
Phase 1
Indian 
Phase 2
Total no. n  168  246  50  111  51  68  67  67 
Mean age – years  
(SD)
45 (13) 55.8 (13) 50 (9) 58 (13) 39 (15) 52 (11) 46 (13) 57 (13)
Males – n (%) 90 (53.5%) 140 (56.9%) 22 (44%) 64 (57.7%) 27 (52.9%) 36 (52.9%) 44 (65.6%) 40 (59.7%)
Smokers – n (%) 26 (13.6%) 24 (9.7%) 4 (8%) 10 (9%) 14 (27.4%) 5 (7%) 16 (23.8%) 9 (13.4%)
Socioeconomic status:  
Private – n (%)
168 (100%) 65 (26.4%) 50 (100%) 32 (28.8%) 51 (100%) 7 (10.3%) 67 (100%) 26 (38.8%)
Mean BMI (kg/m2) 25.1 (5.4) 27.6 (5.3) 23.3 (4.5) 26.3 (4.7) 26.3 (6.4) 30.4 (5.5) 25.6 (4.8) 26.7 (4.8)
Mean systolic blood  
pressure (SD)
125.1 (12.8) 135.0 (19.8) 125.7 (13.7) 135.8 (20.6) 125.1 (12.1) 136.5 (17.5) 124.6 (12.7) 132.3 (20.7)
Mean diastolic blood  
pressure (SD)
78.7 (10.1) 73.4 (10.3) 79.5 (8.9) 73.7 (10.6) 76.9 (10.5) 73.1 (9.7) 79.5 (10.5) 73.1 (10.3)
HbA1c (%) nD 8.1 (1.7) nD 7.9 (1.8) nD 8.5 (1.7) nD 8.0 (1.7)
Mean fasting glucose  
mmol/L (SD)
5.2 (1.2) nD 4.9 (0.5) nD 5.2 (0.7)  nD 5.5 (1.8) nD
Mean total cholesterol 
mmol/L (SD)
5.3 (1.0) 4.6 (1.2) 5.7 (1.2) 4.6 (1.2) 5.3 (1.04) 4.9 (1.3) 5.1 (0.9) 4.2 (0.7)
Mean HDL-C mmol/L  
(SD)
1.3 (0.4) 1.1 (0.4) 1.5 (0.4) 1.2 (0.5) 1.3 (0.3) 1.1 (0.3) 1.1 (0.7) 1.0 (0.3)
Mean LDL-C mmol/L  
(SD)
3.5 (0.8) 2.7 (0.9) 3.6 (0.9) 2.7 (0.8) 3.5 (0.9) 3.1 (1.1) 3.5 (0.8) 2.6 (0.6)
Mean triglyceride mmol/L  
(SD)
1.2 (1.0) 1.4 (0.9) 1.2 (1.4) 1.4 (0.9) 1.1 (0.9) 1.7 (1.0) 1.2 (0.7) 1.4 (0.9)
Mean hs-CRP mg/L 2.04 (2.06) 2.59 (2.34) 1.37 (1.60) 2.02 (2.18) 1.85 (1.70) 3.05 (2.38) 2.69 (2.40) 3.07 (2.38)
Median hs-CRP (25%–75%)  
mg/L
1.2 (0.5–3.1) 1.9 (0.7–4.0) 0.6 (0.2–2.2) 1.2 (0.3–3.3) 1.2 (0.6–2.4) 2.2 (1.1–4.3) 1.9 (0.8–4.0) 2.3 (1.2–4.2)
Abbreviations: BMi, body mass index; hbA1c, glycated hemoglobin; hDL-c, high-density lipoprotein cholesterol; hs-crP, high-sensitivity c-reactive protein; LDL-c, low-
density lipoprotein cholesterol; n, number; nD, not done; SD, standard deviation.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  ethnicity BMI, blood pressure, and cholesterol profile 
 ( Figure 3, Supplementary Table 1).
Amongst individuals in Phase 1, we saw a statistically 
significant association between hs-CRP and Indian ethnicity 
(P = 0.05), BMI (P , 0.001), female sex (P = 0.005), fasting 
glucose (P = 0.047), smokers (P = 0.013), and fasting trig-
lyceride concentrations (P = 0.08) (Supplementary Table 2). 
By performing a robust regression analysis in patients with 
diabetes, we saw a significant positive association of hs-CRP 
with Indian ethnicity (P , 0.001), female sex (P = 0.02), 
BMI (P , 0.001), and a negative association with the use of 
metformin (P = 0.002) (Supplementary Table 3). The mean 
hs-CRP concentrations were higher in the Malays as com-
pared to the Chinese but lower than the Indians. However, 
after adjusting for the various factors, this was not statisti-
cally significant.
Discussion
The ethnic diversity in Singapore reflects three genetic 
roots in Asia (the most populous nations in the world), 
mainly China, India, and Malaysia/Indonesian. Our paper 
examines the ethnic differences in hs-CRP among a   hospital 
sample of Singaporean subjects with and without type 2 
diabetes   mellitus. In our study of the multiethnic population 
of   Singapore (comprising Chinese, Malays, and Indians) 
hs-CRP concentrations were found to be higher in Indians 
when compared to Chinese (P , 0.05) even after adjustment 
for age, sex, BMI, blood pressure, smoking status, and lipid 
profile regardless of whether the patient had diabetes or 
not. Our study also shows that hs-CRP concentrations are 
significantly higher in patients with diabetes when compared 
to patients without diabetes in all three ethnic groups. This 
association again is independent of age, sex, BMI, lipid 
profile, ethnicity, blood pressure, lipid profile, and smoking 
status. Females also had a significantly higher hs-CRP.
Our data is consistent with what others have found, 
in that Indians have a higher hs-CRP when compared to 
other populations in various studies.5,9–11 In the National 
Health Survey (of Singapore) 2004, Indians had the highest 
prevalence of diabetes among the three ethnic groups (15.3% 
compared to 11.0% in Malays and 7.1% in Chinese). It has 
also been seen that amongst patients with diabetes, Indians 
are most ethnically prone to develop CHD followed by the 
Malays and then the Chinese.14 This correlates also with the 
increased susceptibility of Indians to develop CHD both in 
populations with or without diabetes mellitus.
Our study shows that hs-CRP concentrations are signifi-
cantly higher in females when compared to males, which 
is also consistent with previous observations.15 BMI has 
been known to be associated with high hs-CRP.16 Adjust-
ing accordingly for BMI, the hs-CRP is higher in patients 
with diabetes compared with those without diabetes. The 
only long-term study to see the effects of antidiabetic 
drugs on hs-CRP – A Diabetes Outcome Progression Trial 
(ADOPT) – showed the highest reduction of hs-CRP with 
rosiglitazone (60%), followed by metformin (40%) and 
glyburide (20%).17 In our study, hs-CRP was significantly 
lower in patients with diabetes taking metformin when 
Table 2 Percentage of patients on various drugs for the treatment 
of diabetes mellitus and others in Phase 2
Phase 2 (All) Chinese Malays Indians
Total no (%) 246 (100%) 111 (100%) 68 (100%) 67 (100%)
Aspirin  95 (38.6%) 37 (33.3%) 27 (39.7%) 31 (46.3%)
Statin  203 (82.5%) 82 (73.9%) 61 (89.7%) 60 (89.6%)
Ace-i/ArB 164 (66.7%) 70 (63.0%) 48 (70.6%) 46 (68.7%)
Metformin 191 (77.6%) 81 (73.0%) 57 (83.8%) 53 (79.1%)
rosiglitazone 22 (8.9%) 14 (12.6%) 2 (2.9%) 6 (8.9%)
Sulfonylurea 116 (47.2%) 57 (51.4%) 31 (45.6%) 28 (41.8%)
Acarbose 12 (4.9%) 5 (4.5%) 5 (7.4%) 2 (3.0%)
glinides 1 (0.4%) 1 (0.9%) 0 (0%) 0 (0%)
insulin 112 (45.5%) 40 (36%) 40 (58.8%) 32 (47.8%)
Abbreviations: Ace-i/ArB,  angiotensin-converting  enzyme  inhibitor/angiotensin 
receptor blockers.
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Figure 2A Phase 1: high-sensitivity c-reactive protein (hs-crP) concentrations in 
individuals without diabetes mellitus.
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compared to patients without metformin, consistent with 
its insulin-sensitizing action. Although we would expect 
rosiglitazone to have a demonstrable effect on hs-CRP 
reduction, its lack of any statistically significant effect in 
our study probably lies in the small number of patients on 
rosiglitazone when compared to the either metformin or 
sulfonylurea group.
Higher hs-CRP concentrations in Indians has been 
  attributed to higher BMI, higher insulin resistance, and higher 
frequency of metabolic syndrome; however a meta-analysis 
has shown that even after adjustment of these variables, the 
South Asians (Indians) have higher hs-CRP values than 
people of European descent.18 Since our data shows that 
the hs-CRP concentrations were significantly higher in the 
Indians compared to Chinese even after adjustment for BMI, 
blood pressure and lipid profile, it suggested that these fea-
tures of metabolic syndrome alone may not account for the 
variation in the hs-CRP concentrations.
Socioeconomic status has also been seen to be   associated 
with hs-CRP concentrations and with the incidence of coro-
nary artery disease.19–21 In our study, we adjusted for the 
socioeconomic status using the financial status of the indi-
viduals as a surrogate marker. Even after correction for the 
socioeconomic status in this manner, it was seen that hs-CRP 
was higher in the Indians when compared to the Chinese.
Our main limitation is that the sample population is the 
population visiting the hospital for health screening in Phase 1 
and for treatment of diabetes mellitus in Phase 2. Although 
there is a difference in the socioeconomic status of differ-
ent ethnic groups, with the median household income being 
$1504 for Malays, $1882 for Indians, and $2138 for Chinese 
as found in our local National Health Survey in 2000,1 this 
status was different in our study as only relatively complicated 
patients are referred to the hospitals for management. Hence, 
we used the granting of government subsidies as a surrogate 
marker for the socioeconomic status though we recognize 
that this assumption may not be robustly accurate. Our study 
is also limited by its cross-sectional design, which precludes 
conclusions regarding any cause-and-effect relationships. 
Furthermore, we did not adjust for waist circumference, body 
fat percentage, physical activity and homeostasis model assess-
ment of insulin resistance (HOMA-IR) as these were not done. 
We also did not have an accurate data collection regarding the 
exact dose and duration of medications used by our diabetic 
patients, so we could not adjust for the dose and duration.
The results of our study imply that the Indians have higher 
hs-CRP concentration which is a marker for low grade inflam-
mation independent of other variables. Therapeutics to target 
hs-CRP may be warranted in these individuals. As seen in the 
Justification for the Use of Statins in Primary Prevention: An 
Intervention Trial Evaluating Rosuvastatin trial (JUPITER), 
individuals who did not have high LDL-C but who had high 
hs-CRP concentrations benefited from statin therapy in 
terms of reduction of cardiovascular events.22 If we were to 
extrapolate that to our study in Phase 1 (healthy individuals) 
for the Indian subgroup, 18% would be JUPITER-eligible 
compared to Chinese (10%) and Malays (15.6%). Analysis of 
the JUPITER trial showed that the achieved hs-CRP concen-
trations were predictive of event rates irrespective of the lipid 
endpoint used. They saw a reduction of events by up to 79% in 
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patients who achieved the targets of LDL-C ,1.8 mmol/L 
and   hs-CRP ,1mg/L with statin treatment.23 Therapeutics 
to target more intensive control of other traditional cardio-
vascular risk factors may also be warranted in this subgroup 
of patients. For instance, it has been seen that the body fat 
percentage for a given BMI may be higher in Indians when 
compared to the Chinese and the Malays. Hence, a lower 
cutoff for BMI to define obesity has been proposed for the 
Indians.24
We show that Indians have the highest hs-CRP concen-
trations, and since we know that they also are at the greatest 
risk of cardiovascular events, it would be logical to demon-
strate that reducing hs-CRP concentrations can reduce the 
cardiovascular risk of this high risk population in line with 
Bradford Hill’s criteria of proving causality.25 Future inves-
tigations that probe the role of genetic variants and other 
environmental factors that may influence the concentrations 
of hs-CRP in the three ethnic groups will also shed more 
light onto this matter.
Conclusions
We have found that Indian patients with diabetes have the 
highest hs-CRP concentration in our ethnically diverse popu-
lation. This mirrors the higher risk of CHD in the Indians 
and therapeutics targeting hs-CRP may thus be a priority in 
addition to intensive control of traditional cardiovascular 
risk factors.
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Supplementary Table 1 robust regression in Phase 1 and Phase 2
Coefficient P . |t| 95% lower CI 95% upper CI
Phase 1 reference – – –
Phase 2 0.464 0.034 0.036 0.892
Age (years) −0.010 0.123 –0.023 0.003
Sex
  Males reference – – –
  Female 0.617 0.001 0.271 0.962
race
  chinese reference – – –
  Malay 0.153 0.467 −0.231 0.581
  indian 0.893 ,0.001 0.442 1.232
BMi 0.102 ,0.001 0.070 0.133
Systolic BP (mmhg) 0.002 0.759 −0.009 0.013
Diastolic BP (mmhg) 0.005 0.589 −0.013 0.024
Total cholesterol (mmol/L) 0.125 0.867 −1.342 1.593
hDL-c (mmol/L) 0.050 0.954 −1.641 1.741
LDL-c (mmol/L) 0.149 0.841 −1.308 1.605
Triglycerides (mmol/L) 0.432 0.224 −0.265 1.129
Smoking status
nonsmokers reference – – –
Smokers −0.080 0.748 −0.408 0.568
constant −4.645 ,0.001 −6.604 −2.687
Abbreviations: BP, blood pressure; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Supplementary Table 2 robust regression in Phase 1
Coefficient P-value 95% lower CI 95% upper CI
Age −0.013 0.132 −0.031 0.004
Sex
  Male reference – – –
  Female  0.627 0.005 0.196 1.058
race
  chinese reference – – –
  Malay −0.198 0.460 −0.725 0.329
  indian  0.508 0.051 −0.002 1.017
Smoking status
  nonsmokers reference – – –
  Smokers  −0.708 0.013 −1.267 −0.149
BMi  0.100 ,0.001 0.060 0.139
Systolic BP (mmhg) −0.017 0.103 −0.037 0.003
Diastolic BP (mmhg) 0.014 0.308 −0.013 0.041
Fasting glucose (mmol/L) 0.164 0.047 0.002 0.327
cholesterol (mmol/L) −1.685 0.194 −4.234 0.864
hDL-c (mmol/L) 1.531 0.229 −0.972 4.034
LDL-c (mmol/L) 1.887 0.146 −0.662 4.437
Tg (mmol/L) 1.493 0.008 0.397 2.589
constant  −2.526 0.056 −5.122 0.070
Abbreviations: BP, blood pressure; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.
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Supplementary Table 3 robust regression in Phase 2
Coefficient P-value 95% lower CI 95% upper CI
Age −0.016 0.192 −0.040 0.008
Sex
  Male reference – − –
  Female  0.663 0.024 0.089 1.238
race
  chinese reference – – –
  Malay 0.348 0.326 −0.349 1.046
  indian  1.206 0.000 0.551 1.862
Smoking status
  nonsmokers reference – – –
  Smokers 0.294 0.504 −0.571 1.158
Se status
Se private reference – – –
Se subsidized 0.309 0.332 −0.317 0.936
BMi  0.101 0.000 0.047 0.154
Systolic BP (mmhg) 0.004 0.581 −0.012 0.021
Diastolic BP (mmhg) 0.007 0.640 −0.023 0.037
hbA1c (%) 0.056 0.532 −0.120 0.231
cholesterol (mmol/L) 0.433 0.704 −1.807 2.673
hDL-c (mmol/L) −0.212 0.880 −2.968 2.545
LDL-c (mmol/L) −0.325 0.774 −2.547 1.897
Tg (mmol/L) 0.169 0.760 −0.919 1.257
Aspirin 0.015 0.958 −0.559 0.590
Statin −0.022 0.951 −0.727 0.683
Ace/ArB 0.084 0.775 −0.494 0.662
rosiglitazone −0.049 0.919 −1.006 0.907
Metformin  −1.035 0.002 −1.695 –0.375
Sulfonylurea 0.429 0.159 −0.170 1.027
insulin 0.171 0.628 −0.524 0.865
Acarbose −0.092 0.879 −1.279 1.094
glinides −1.250 0.535 −5.213 2.713
constant  −3.829 0.030 −7.287 –0.372
Abbreviations: ACE/ARB, angiotensin-converting enzyme/angiotensin receptor blockers; BMI, body mass index; BP, blood pressure; CI, confidence interval; HbA1c, 
glycated hemoglobin; hDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; Se, socioeconomic status; Tg, triglyceride.